NCT03013491 - PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

January 19, 2017

Primary Completion Date

October 27, 2020

Study Completion Date

October 27, 2020

Conditions

Solid TumorLymphoma

Interventions

DRUG

CX-072

Solution for infusion

DRUG

ipilimumab

Solution for infusion

DRUG

vemurafenib

Tablet

Trial Locations (31)

1007

PROCLAIM Investigative Site, Amsterdam

8036

PROCLAIM Investigative Site, Barcelona

10016

PROCLAIM Investigative Site, New York

10032

PROCLAIM Investigative Site, New York

10065

PROCLAIM Investigative Site, New York

22031

PROCLAIM Investigative Site, Fairfax

28046

PROCLAIM Investigative Site, Madrid

28050

PROCLAIM Investigative Site, Madrid

31008

PROCLAIM Investigative Site, Pamplona

37203

PROCLAIM Investigative Site, Nashville

46009

PROCLAIM Investigative Ssite, Valencia

46202

PROCLAIM Investigative Site, Indianapolis

48201

PROCLAIM Investigative Site, Detroit

49102

PROCLAIM Investigative Site, Dnipro

53579

PROCLAIM Investigative Site, Madison

60612

PROCLAIM Investigative Site, Chicago

75230

PROCLAIM Investigative Site, Dallas

77030

PROCLAIM Investigative Site, Houston

90025

PROCLAIM Investigative Site, Los Angeles

90033

PROCLAIM Investigative Site, Los Angeles

97213

PROCLAIM Investigative Site, Portland

06520

PROCLAIM Investigative Site, New Haven

02215

PROCLAIM Investigative Site, Boston

9713 GZ

PROCLAIM Investigative Site, Groningen

3000 CA

PROCLAIM Investigative Site, Rotterdam

40-960

PROCLAIM Investigative Site, Katowice

08908

PROCLAIM Investigative Site, Barcelona

G12 0YN

PROCLAIM Invetigative Site, Glasgow

W1G 6AD

PROCLAIM Investigative Site, London

M20 4BX

PROCLAIM Investigative Site, Manchester

NE7 7DN

PROCLAIM Investigative Site, Newcastle upon Tyne